Durvalumab Earns FDA Priority Review for Early-Stage Gastric Cancer

AstraZeneca's Imfinzi gains FDA priority review

This designation is granted for treatments that could significantly improve upon existing options. The FDA’s decision is expected by the fourth quarter of 2025, in line with the The post AstraZeneca’s Imfinzi gains FDA priority review appeared first on Pharmaceutical Business review.

Durvalumab Earns FDA Priority Review for Early-Stage Gastric Cancer

Durvalumab's breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies.